adplus-dvertising
Connect with us

Health

Nurse texts dad, asking for ventilators, and a prototype is together in six days – Toronto Star

Published

 on


Saskatoon– A few days after the global pandemic was declared, Jim Boire got a text from his daughter. Rebecca Erker, a Royal University Hospital intensive care unit nurse. She is working on her PhD with the respiratory research centre in Saskatoon. As a result, she had a good understanding of what was at stake with COVID-19, and reason to be concerned.

Thankfully, Boire is president of RMD Engineering, a Saskatoon firm whose expertise ranges from beamlines for the Canada Light Source Synchrotron to industrial processes in potash mining, and a whole lot in between. They’ve worked in uranium, agriculture, and a lot of research and development. His company (which Boire owns with four other partners, all employees) had the expertise and capacity to do something about it. And so they did.

“I got my text from my daughter on March 18. March 24, we had our first prototype built,” Boire said by phone on Dec. 3. Now the Saskatchewan Health Authority (SHA) announced on that December day it would be taking delivery of 100 new ventilators, known as the EUV-SK1, in short order. The first 20 are ready to go out the door, and the company has most of the parts in place to build as many as 1,000 units.

300x250x1

RMD Engineering Inc.’s subsidiary, One Health Medical Technologies, recently received COVID-19 Medical Device Authorization from Health Canada for an in-house designed, developed and manufactured ventilator. Collaborating with the University of Saskatchewan and SHA subject matter experts, RMD Engineering was able to successfully prototype an emergency use ventilator for Health Canada certification.

According to a Ministry of Health press release on Dec. 3, there are currently approximately 650 ventilators available in Saskatchewan’s health system, enough to meet the need. They range from high-end critical care type ventilators to more basic sub-acute ventilators. The SHA’s purchase from RMD will increase that number to about 750.

But getting from a text to a prototype for an approved ventilator wasn’t easy, nor was it quick process.

Very early on, the deans of both the University of Saskatchewan College of Engineering and College of Medicine got involved. Top respiratory technologies, respirologists, and ICU nurses were brought in within short order to develop this totally new product. Boire said, “As soon as we asked for them to help, they helped with open arms. And you have a team like that that knows exactly what something is supposed to do. And the capability to build something that can do that, then all you need are the codes and standards and validation equipment to make sure it meets the required level of quality.”

Asked if it was like converting to war production in 1940, Boire said, “I’ll tell you, that’s exactly the way it started.

“It felt like a military operation, if I was ever involved in a military operation, but I wasn’t. However, as soon as we got through the point where this is going to work, this design is going to work, here’s what we have to do now, a group of people said, ‘You know what? We get it. This is like a military operation, everybody’s doing this, let’s just go go go.’

“They stopped and said, “You know what, it’s probably time now that everybody starts looking at this as the biggest humanitarian effort this company has ever done.” And it was just an awesome way to get out of that firefighting mode. And then one of our instrumentation leads said, ‘This is not a sprint. You guys can’t keep working 18 hours a day. This is going to be a marathon.’

“And it really helped pull the whole team back down to the ground, and get them out of that adrenaline mode, and really start focusing on the work breakdown, structure in the tasks at hand, and who’s responsible for what and what’s this timing going look like and when is this going in.”

His references to firefighting are authentic, as the company has built support equipment for water bombers.

Worldwide shortages

They soon realized that the whole world was looking for critical parts, which almost immediately went into short supply and were being hoarded. Some items, like wire, saw huge price spikes. So RMD quickly realized it had to work on this project quietly, and develop a product that avoided critical path component shortages.

Boire said, “Instead of using the newer, more conventional turbine method, we knew those would be a hot commodity, when the world proclaimed they needed over a million of these. As you can imagine, that turbine is a complicated piece of equipment. We went the other way. We went back to being simple,” Boire said. “We have very, very few moving parts in our machine. There’s four moving parts.”

He explained, “This is an emergency use ventilator, so it needs to be used in the hospital or in an emergency hospital situation where they have line medical air and line oxygen so that’ll be running at 50 PSI. And then we control everything with proportional solenoids.”

There are two tubes coming into the device, which is in a large Pelican case, and two tubes coming out. They had them on hand because of another government project they’re working on. The lid includes an IBM screen.

“They’re all high reliability components,” he said. It runs off 110 volt AC power.

You set it up beside the bed, hook up the lines, hook up the power and put in the appropriate prescription.

High standards

They had previously made the biomedical imaging line for the Canadian Light Source, but they weren’t a medical device manufacturer. The list of specifications, protocols and standards was extensive.

And those standards, in some ways, simplify things. Boire said, “We don’t have any proprietary stuff on there, so all of the circuits, all the nebulizers everything fits on there. All that is covered off in standards. And I think that’s one of the biggest things to understand is when you go down this path, it is very prescriptive on everything. The machine has to do all of the standards it has to meet, including operational standards.”

He added, “It’s probably a foot tall, the stack of standards, when you put them together. You have to meet the electrical requirements, the operational requirements, the safety requirements. You don’t get to just build something in your backyard, and then tell everybody you have it. When you go and look at the requirements, when you submit to Health Canada, it is an armful. And I think we’ve spent just about $30,000 on standards. There is a lot of standards that you have to meet.”

It is very unique, he said. “We looked at the critical components like flow meters, how you measure flow and pressure, because we’re talking very low pressures that have to be measured very accurately.”

This is where the consultation with respiratory technicians, anesthesiology repair technicians from the health region made a difference. Because there was such high demand for ventilator components, he said, “You have to figure out how to do that with readily available things that are very safe.”

“So when we started doing our production testing, we had to do accelerated testing on components that, in the period of two or three weeks, we could get an effective 25 million cycles on a component that we designed.”

By the end of December, they’ll likely have the remaining 80 units ready. They’ve also built a training version to be used in remote areas or to train people on a simulation patient or a “test lung.”

Loading…

Loading…Loading…Loading…Loading…Loading…

They submitted their application to Health Canada on May 5. “In that period of time is when we refined our design, did our testing, had to send it out to third party,” Boire said.

Commitment

Quality assurance and traceability were very important, he said.

“Since March, we’ve got 40,000 to 45,000 hours in already, in the development and testing and verification side.”

This happened just as the company was in the middle of expanding their facility, much of which was accomplished with their own staff.

“We’re probably going have to hire another 12 to 15 people, and train them,” he said, noting training is a big part when dealing with healthcare devices, especially when it comes to things like quality control.

“We’ve currently got 15 people now on the manufacturing side of it and the programing side, and the testing side.”

They are working on getting their Medical Device Single Audit Program (MDSAP) certification, which he calls a “quality control program on steroids.”

Asked if they were going to stick with it, he said, “We’re going to stay as a medical manufacturer.”

Boire added, “The medical device manufacturing will just be another part of our company. We’re going to stay with theses rugged use ventilators, like this emergency type ventilator. We do not intend to compete with Panasonic or anybody at Philips, anybody that’s making mainstream, high-volume ventilators. We’ll stay with a rugged use ventilator, because unfortunately, when you look at the numbers and look at this type of virus, the feeling is this could be around for a long time. And the government is coming out with a program that those of us that produced a medical device will have the opportunity over the next couple of years to convert that to a full medical device licence. And we’ll take advantage of that just so we can make sure we keep this, here in Saskatchewan. We’ve already spent the money. Whatever happens now, happens.

“So we want to make sure that we leverage that into good technology and good expertise for the years to come, not just, ‘Oh well, there’s no more ventilators to make, we’ll just do something else.’

Boire said they found that Saskatchewan really needs to focus more on trades and “getting trades educated with higher-end things.”

“We have to bring manufacturing back to Saskatchewan,” he said.

They were going to do it

Why did they choose 1,000 units? Boire explained, “Saskatchewan said, ‘Our numbers show we need 1,000 ventilators in Saskatchewan.’

“We’re from Saskatchewan. We said we’re going to pick to do this, based on what we can do in this province. And what we did instead is while we were building this, we’ve built a whole project management system and basically a tool kit that if need be, if this type of ventilator is required in other places, we now have a system that we can go and work with another company very similar to ours, that has similar manufacturing capabilities and get them up and running to produce locally to them.”

Boire said, “If we sold, half of what we had expected to make, we will break even. But again, it’s not why we did it.”

“This initiative exemplifies the spirit of collaboration and entrepreneurship we’re so proud of in our province,” Health Minister Paul Merriman said in a release. “Our government fully supports this work, and we are pleased that residents in Saskatchewan and across the country will have access to this equipment, if they need it.”

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Health

Business Plan Approved for Cancer Centre at NRGH – My Cowichan Valley Now

Published

 on


A business plan for a new BC Cancer Centre at Nanaimo Regional General Hospital has been approved by the province. 

 

Health Minister Adrian Dix  says the state-of-the-art cancer facility will benefit patients in Nanaimo and the surrounding region through the latest medical technology.
 

300x250x1

The facility will have 12 exam rooms, four consultation rooms and space for medical physicists and radiation therapists, medical imaging and radiation treatment of cancer patients. 

 

The procurement process is underway, and construction is expected to begin in 2025 and be complete in 2028. 

 

Upgrades to NRGH have also been approved, such as a new single-storey addition to the ambulatory care building and expanded pharmacy. 

 

Dix says Nanaimo’s population is growing rapidly and aging, and stronger health services in the region, so people get the health care they need closer to home. 

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Outdated cancer screening guidelines jeopardizing early detection, doctors say – Powell River Peak

Published

 on


A group of doctors say Canadian cancer screening guidelines set by a national task force are out-of-date and putting people at risk because their cancers aren’t detected early enough. 

“I’m faced with treating too many patients dying of prostate cancer on a daily basis due to delayed diagnosis,” Dr. Fred Saad, a urological oncologist and director of prostate cancer research at the Montreal Cancer Institute, said at a news conference in Ottawa on Monday. 

The Canadian Task Force on Preventive Health Care, established by the Public Health Agency of Canada, sets clinical guidelines to help family doctors and nurse practitioners decide whether and when to recommend screening and other prevention and early detection health-care measures to their patients.

300x250x1

Its members include primary-care physicians and nurse practitioners, as well as specialists, a spokesperson for the task force said in an email Monday. 

But Saad and other doctors associated with the Coalition for Responsible Healthcare Guidelines, which organized the news conference, said the task force’s screening guidelines for breast, prostate, lung and cervical cancer are largely based on older research and conflict with the opinions of specialists in those areas. 

For example, the task force recommends against wide use of the prostate specific antigen test, commonly known as a PSA test, for men who haven’t already had prostate cancer. Saad called that advice, which dates back to 2014, “outdated” and “overly simplistic.” 

The task force’s recommendation is based on the harms of getting false positive results that lead to unnecessary biopsies and treatment, he said. 

But that reasoning falsely assumes that everyone who gets a positive PSA test will automatically get a biopsy, Saad said. 

“We are way beyond the era of every abnormal screening test leading to a biopsy and every biopsy leading to treatment,” he said, noting that MRIs can be used to avoid some biopsies.

“Canadian men deserve (to) have the right to decide what is important to them, and family physicians need to stop being confused by recommendations that go against logic and evidence.”

Dr. Martin Yaffe, co-director of the Imaging Research Program at the Ontario Institute for Cancer Research, raised similar concerns about the task force’s breast cancer screening guideline, which doesn’t endorse mammograms for women younger than 50.

That’s despite the fact that the U.S. task force says women 40 and older may decide to get one after discussing the risks and benefits with their primary-care provider. 

The Canadian task force is due to update its guidance on breast cancer screening in the coming months, but Yaffe said he’s still concerned.

“The task force leadership demonstrates a strong bias against earlier detection of disease,” he said.

Like Saad, Yaffe believes it puts too much emphasis on the potential harm of false positive results.

“It’s very hard for us and for patients to balance this idea of being called back and being anxious transiently for a few days while things are sorted out, compared to the chance of having cancer go undetected and you end up either dying from it or being treated for very advanced disease.”

But Dr. Eddy Lang, a member of the task force, said the harms of false positives should not be underestimated. 

“We’ve certainly recommended in favour of screening when the benefits clearly outweigh the harms,” said Lang, who is an emergency physician and a professor at the University of Calgary’s medical school. 

“But we’re cautious and balanced and want to make sure that we consider all perspectives.” 

For example, some men get prostate cancer that doesn’t progress, Lang said, but if they undergo treatments they face risks including possible urinary incontinence and erectile dysfunction. 

Lang also said the task force monitors research “all the time for important studies that will change our recommendations.” 

“And if one of them comes along, we prioritize the updating of that particular guideline,” he said. 

The Canadian Cancer Society pulled its endorsement from the task force’s website in December 2022, saying it hadn’t acted quickly enough to review and update its breast cancer screening guidelines to consider including women between 40 and 50. 

“(The Canadian Cancer Society) believes there is an obligation to ensure guidelines are keeping pace with the changing environment and new research findings to ensure people in Canada are supported with preventative health care,” it said in an emailed statement Monday evening. 

Some provinces have implemented more proactive early detection programs, including screening for breast cancer at younger ages, using human papillomavirus (HPV) testing to screen for cervical cancer and implementing CT scanning to screen for lung cancer, doctors with the Coalition for Responsible Healthcare Guidelines said. 

But that leads to “piecemeal” screening systems and unequal access across the country, said Dr. Shushiela Appavoo, a radiologist with the University of Alberta.

Plus, many primary-care providers rely on the national task force guidelines in their discussions with patients, she said. 

“The strongest association … with a woman actually going for her breast cancer screen is whether or not her doctor recommends it to her. So if her doctor is not recommending it to her, it doesn’t matter what the provincial guideline allows,” Appavoo said. 

In addition to updating its guideline for breast cancer screening this spring, the task force is due to review its guidelines for cervical cancer screening in 2025 and for lung cancer and prostate cancer screening in 2026, according to its website.

This report by The Canadian Press was first published April 16, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

Nicole Ireland, The Canadian Press

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Opioid Deaths Doubled Across Canada After Pandemic Onset – Medscape

Published

 on


Premature opioid-related deaths doubled in Canada after the onset of COVID-19 pandemic, and more than one in four deaths occurred in young adults, a new study suggested.

“The intersection of the COVID-19 pandemic with the drug toxicity crisis in Canada has created an urgent need to better understand the patterns of opioid-related deaths across the country to inform targeted public health responses,” the study authors wrote.

Some Canadian provinces were disproportionately affected by the crisis, they noted. For example, in Alberta, close to half of all deaths among people aged 20-39 years were opioid-related.

300x250x1
Shaleesa Ledlie

“Although the finding that the early loss of life was increasing over time was expected, the magnitude of this burden across Canada surprised me,” lead author Shaleesa Ledlie, MPH, a PhD candidate at the Leslie Dan Faculty of Pharmacy of the University of Toronto, Toronto, Ontario, Canada, told Medscape Medical News.

In addition to the increase in Alberta, she said, “in Manitoba, opioid-related death rates and the associated years of life lost increased almost fivefold between 2019 and 2021. This really reinforces the urgency of this issue across Canada and identifies regions where focused attention might be warranted.”

The study was published online on April 15 in Canadian Medical Association Journal.

Significant Increases

Researchers conducted a repeated cross-sectional analysis of accidental opioid-related deaths from 2019 through 2021 in nine Canadian provinces and territories. All provinces and territories for which age- and sex-stratified data were available at the time of the study were included: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, and the Northwest Territories. These areas represent 98% of Canada’s population.

Deaths were determined to be accidental or intentional by the coroner or medical examiner in each province or territory who investigated the death, according to Ledlie.

The primary outcome was the burden of premature opioid-related death, measured by potential years of life lost (YLL). The secondary outcome was the proportion of deaths attributable to opioids.

Overall, the annual YLL from opioid-related deaths doubled during the study period, from 3.5 YLL per 1000 population in 2019 to 7.0 YLL per 1000 in 2021.

In 2021, the highest burdens of death were observed among men (9.9 YLL per 1000) and young adults aged 20-29 years (12.8 YLL per 1000) and 30-39 years (16.5 YLL per 1000).

More than 70% of all opioid-related deaths occurred among men each year (73.9% in 2021), and about 25% of deaths occurred among people between the ages of 30 and 39 years (29.5% in 2021).

Geographic Variation

The annual increases by age and sex in each province and territory were generally consistent with the overall analysis. The observed changes in YLL over time varied geographically, however. They ranged from a 0.8-fold decrease in Nova Scotia (1581 YLL in 2019 to 1324 YLL in 2021) to a 4.7-fold increase in Manitoba (2434 YLL in 2019 to 11,543 YLL in 2021).

In 2021, the rate of YLL ranged from a low of 1.4 per 1000 in Nova Scotia to a high of 15.6 per 1000 in Alberta, whereas the absolute number of YLL ranged from 93 in the Northwest Territories to 111,633 in Ontario.

Between 2019 and 2021, the average percentage of all deaths attributed to opioids increased in all age groups. In 2019, 1.7% of deaths among people younger than 85 years were related to opioids. This proportion increased to 3.2% of deaths in 2021.

The largest relative increase between 2019 and 2021 (50.3%) was among young people. Opioid-attributable deaths increased from 19.3% to 29.0% among those aged 30-39 years. This change was followed by a 48.0% increase among those aged 20-29 years from 19.8% to 29.3%.

The authors noted that the study was limited by their inability to examine four provinces and territories for which the numbers of opioid-related deaths were suppressed because of small counts (ie, < 5). However, sensitivity analyses suggested that the demographic distribution of these deaths followed a pattern like that of the overall results.

More Information Needed

Commenting on the study for Medscape Medical News, S. Monty Ghosh, MD, MPH, an assistant professor at the University of Alberta, clinical assistant professor at the University of Calgary, and co-medical lead of Alberta Health Services’ Rapid Access Addiction Medicine program in Calgary, said, “The study was fairly robust in its evaluation. Their approach statistically is sound and makes sense, given the quality of data they received.” Ghosh did not participate in the analysis.

photo of Monty Ghosh
S. Monty Ghosh, MD

It would be important to know whether the premature deaths were polysubstance related, he noted. “More nuanced data in Alberta demonstrated that most of the deaths are related to polysubstance use on top of fentanyl. This includes alcohol, meth, as well as substance contaminants such as benzodiazepines, and more lately (outside of the research period), xylazine.”

Furthermore, Ghosh added, “It would be good to see more demographic information around the youth in Alberta. For instance, were they housed or unhoused? Are they Indigenous? Anecdotally, we know that blue-collar workers, especially those in Alberta who work in construction and oil rigs, have a disproportionate rate of substance use and at times substance death. This was seen in British Columbia and Ontario.”

What’s Being Done

The government of Alberta is responding to these data, said Ghosh. For example, in 2022, specialized funding was provided to enable young adults to access gold-standard opioid agonist treatment. The treatment was rolled out through Alberta’s Virtual Opioid Dependency Program (VODP) and other community-based addiction programs. “This [program] still needs to be more focused on homeless youth, however, who may not have access to technology or other resources.”

Furthermore, the government recently announced a $1.55-billion plan to continue building the Alberta Recovery model, he said. “This is the largest investment seen in our province. Safer supply or prescribed alternatives is very controversial in Alberta and thus is not an option available to this population.”

In addition, he said, the Ministry of Seniors and Community Social Services recently began “coordinated work with other ministries to support vulnerable and equity-deserving populations around this issue, including creating navigation centers for housing, income support, and access to treatment through the VODP.”

Ledlie noted that various policies and programs have been developed in response to the ongoing drug toxicity crisis. Some were included in a recent review that her team conducted to summarize the evidence from Canadian safer opioid supply programs. “We found that in general, these programs had positive impacts on clients, including reduced rates of opioid toxicities and improvements in quality of life.”

“Because most healthcare is coordinated at the provincial or territorial level, the investments into, and accessibility of, treatment and harm-reduction services tend to vary across Canada,” she said. “Even in regions where these programs exist, we know that they are not always accessible for various reasons, such as a lack of resources preventing widespread expansion and geographic barriers in more remote and rural regions.”

“One example of a simple yet life-saving harm reduction measure that has been effectively implemented by most provincial and territorial governments is the availability of publicly funded naloxone kits,” she added. “Given the widespread societal impacts of opioid toxicities described in our study, we believe it is pivotal for all levels of government to coordinate to ensure equitable access to evidence-based services across the country, while still providing the opportunity to tailor and adapt those responses to the unique needs of local communities.”

The study was supported by grants from the Ontario Ministry of Health and the Canadian Institutes of Health Research. Ledlie is supported by an Ontario Graduate Scholarship and the Network for Improving Health Systems Trainee Award. Ledlie and Ghosh declared no relevant financial relationships.

Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Trending